Whitehawk Therapeutics (WHWK) Assets (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Assets data on file, last reported at $127.2 million in Q1 2026.

• On a quarterly basis, Assets fell 45.63% year-over-year to $127.2 million in Q1 2026; TTM through Mar 2026 was $127.2 million, a 45.63% decrease from a year earlier, with the FY2025 full-year figure at $150.8 million, up 114.49% from the prior year.
• Assets for Q1 2026 stood at $127.2 million, down from $150.8 million in the prior quarter.
• Over the last five years, Assets for WHWK reached as high as $234.0 million in Q1 2025 and fell as low as $70.3 million in Q4 2024.
• Historically, Assets has averaged $145.4 million across 5 years, with a median of $142.3 million in 2022.
• Across the five-year window, Assets surged 245.76% in 2022 and sank 46.9% in 2024, its largest moves.
• Year by year, Assets stood at $184.2 million in 2022, then declined by 28.12% to $132.4 million in 2023, then plunged by 46.9% to $70.3 million in 2024, then surged by 114.49% to $150.8 million in 2025, then retreated by 15.65% to $127.2 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $127.2 million in Q1 2026, $150.8 million in Q4 2025, and $167.0 million in Q3 2025.